PHAROS IBIO
DEAD

Serial Number

79386772

Owner

Pharos iBio Co., Ltd.

Filing Date

Sep 6, 2023

Add to watchlist:

No watchlists yet
View on USPTO

PHAROS IBIO Trademark

Serial Number: 79386772

PHAROS IBIO is a trademark filed by Pharos iBio Co., Ltd. on September 6, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Pharos iBio Co., Ltd. (2 trademarks)

#1408, 38, Heungan-daero 427beon-gil
Dongan-gu, Anyang-si Gyeonggi-do 14059 , KR

Entity Type: 99

Trademark Details

Filing Date

September 6, 2023

Registration Date

Not Registered

Goods & Services

Vaccines; pharmaceutical preparations for the treatment of leukemia; pharmaceutical preparations for the treatment of cells; pharmaceutical preparations and compositions for the treatment and prevention of cancer; biopharmaceuticals for the treatment of cancer; reagents and media for medical and veterinary diagnostic purposes; medicinal healthcare preparations; pharmaceutical drugs; diagnostic agents for pharmaceutical use; medicinal creams; synthetic peptides for pharmaceutical purposes; chemical preparations for pharmaceutical purposes; pharmaceutical compositions; pharmaceuticals; human vaccine preparations; pharmaceutical preparations for tumor treatment; pharmaceutical preparations for the treatment of immune system related diseases and disorders; nutraceuticals for therapeutic purposes; therapeutic drugs and agents; anti-cancer preparations

Scientific research conducted using databases; research and development of vaccines and medicines; analysis in the field of molecular biology; development of computer software for big data processing; research and development of technology for biotechnology; consultancy in the field of biotechnology; research relating to biotechnology; advisory services relating to biotechnology; biotechnology services; biological information check (genetic testing for scientific research purposes); biological information check (genetic testing for medical research purposes); platform as a service [PaaS]; development of cell therapy products; development, updating and maintenance of software and database systems; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; consultancy relating to research in the field of pharmacogenetics; research in the field of pharmacogenetics; pharmaceutical research and development; pharmaceutical research services; scientific research in the field of pharmacy; toxicity testing for research purposes; providing technological consultancy relating to design and development of medical diagnostic instruments; providing computer software technical support services in the field of medical diagnostics; medicine research; providing information on the testing, inspection, and research of medical products, consultancy in the field of testing, inspection, and research of medical products; medical and pharmacological research services; scientific research in the fields of medicine, and health and pharmacology; design and development of programs for computers

Filing History

LIMITATION OF GOODS RECEIVED FROM IB
Sep 11, 2025 LIMG
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 20, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 3, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 3, 2025 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Oct 24, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 24, 2024 ABN2
REFUSAL PROCESSED BY IB
May 1, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 11, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 11, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 23, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 22, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 18, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 9, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 5, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 4, 2024 REPR